A.R.T. Advisors LLC boosted its stake in Geron Co. (NASDAQ:GERN) by 74.3% in the first quarter, Holdings Channel reports. The firm owned 148,700 shares of the biopharmaceutical company’s stock after acquiring an additional 63,400 shares during the period. A.R.T. Advisors LLC’s holdings in Geron were worth $631,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GERN. Geode Capital Management LLC increased its holdings in Geron by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,344,758 shares of the biopharmaceutical company’s stock valued at $2,420,000 after purchasing an additional 25,058 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in Geron in the fourth quarter valued at about $481,000. Renaissance Technologies LLC increased its holdings in Geron by 34.2% in the fourth quarter. Renaissance Technologies LLC now owns 872,115 shares of the biopharmaceutical company’s stock valued at $1,570,000 after purchasing an additional 222,235 shares during the last quarter. Deutsche Bank AG grew its stake in Geron by 70.1% in the fourth quarter. Deutsche Bank AG now owns 696,410 shares of the biopharmaceutical company’s stock valued at $1,251,000 after acquiring an additional 286,979 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in Geron by 97.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 238,143 shares of the biopharmaceutical company’s stock valued at $429,000 after acquiring an additional 117,457 shares during the period. Institutional investors and hedge funds own 34.52% of the company’s stock.
Geron opened at $3.43 on Friday, Marketbeat reports. The stock has a market cap of $609.24 million, a PE ratio of -19.06 and a beta of 2.35. Geron Co. has a fifty-two week low of $1.74 and a fifty-two week high of $6.68.
Geron (NASDAQ:GERN) last posted its quarterly earnings data on Thursday, May 10th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The company had revenue of $0.32 million during the quarter. Geron had a negative return on equity of 26.20% and a negative net margin of 3,300.12%. During the same period in the prior year, the company earned ($0.05) earnings per share.
GERN has been the subject of a number of research analyst reports. ValuEngine raised Geron from a “hold” rating to a “buy” rating in a research note on Wednesday, May 23rd. BidaskClub raised Geron from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 17th. Piper Jaffray Companies reissued a “buy” rating and issued a $7.00 target price on shares of Geron in a research note on Monday, March 19th. Finally, Stifel Nicolaus boosted their target price on Geron from $2.50 to $4.00 and gave the company a “hold” rating in a research note on Sunday, March 18th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $5.17.
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.
Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN).
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.